NRIX
Nurix Therapeutics, Inc. [NRIX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRIX Stock Summary
Top 10 Correlated ETFs
NRIX
Top 10 Correlated Stocks
NRIX
In the News
NRIX Financial details
Company Rating
Sell
Market Cap
818.49M
Income
-142.25M
Revenue
80.89M
Book val./share
3.07
Cash/share
4.44
Dividend
-
Dividend %
-
Employees
284
Optionable
No
Shortable
Yes
Earnings
11 Jul 2024
P/E
-3.9
Forward P/E
-
PEG
1.65
P/S
6.89
P/B
2.27
P/C
3.25
P/FCF
-3.06
Quick Ratio
4.24
Current Ratio
4.36
Debt / Equity
0.17
LT Debt / Equity
0.13
-
-
EPS (TTM)
-2.61
EPS next Y
-
EPS next Q
-
EPS this Y
-22.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
36.46%
Revenue last 5Y
19.86%
Revenue Q/Q
9.41%
EPS Q/Q
-1.3%
-
-
-
-
SMA20
23.08%
SMA50
100%
SMA100
166.67%
Inst Own
54.24%
Inst Trans
0.67%
ROA
-44%
ROE
-51%
ROC
-0.64%
Gross Margin
100%
Oper. Margin
-231%
Profit Margin
-198%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.22-18.12
52W High
-19.94%
52W Low
+260.25%
RSI
51
Rel Volume
0.63
Avg Volume
855.74K
Volume
540.01K
Perf Week
-8.16%
Perf Month
-0.62%
Perf Quarter
226.02%
Perf Half Y
124.8%
-
-
-
-
Beta
2.062
-
-
Volatility
1.19%, 1.17%
Prev Close
2.34%
Price
14.41
Change
-4.57%
NRIX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-11-30
| Metric | History | 2019-11-30 | 2020-11-30 | 2021-11-30 | 2022-11-30 | 2023-11-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.8 | 1.14 | 0.69 | 0.79 | 1.42 | |
| Net income per share | -0.56 | -2.76 | -2.73 | -3.42 | -2.65 | |
| Operating cash flow per share | 0.02 | -0.01 | -1.97 | -3.29 | -1.5 | |
| Free cash flow per share | -0.03 | -0.3 | -2.1 | -3.54 | -1.65 | |
| Cash per share | 0.97 | 17.94 | 6.89 | 6.36 | 5.3 | |
| Book value per share | -1.49 | 18.52 | 7.98 | 6.25 | 3.69 | |
| Tangible book value per share | -1.49 | 18.52 | 7.98 | 6.25 | 3.69 | |
| Share holders equity per share | -1.49 | 18.52 | 7.98 | 6.25 | 3.69 | |
| Interest debt per share | 0.12 | 0.49 | 0.3 | -0.05 | 0.56 | |
| Market cap | 738.45M | 668M | 1.24B | 602.25M | 337.98M | |
| Enterprise value | 703.63M | 548.65M | 1.17B | 549.74M | 313.97M | |
| P/E ratio | -34.03 | -15.45 | -10.55 | -3.63 | -2.35 | |
| Price to sales ratio | 23.73 | 37.49 | 41.55 | 15.59 | 4.39 | |
| POCF ratio | 1.23K | -8.35K | -14.65 | -3.77 | -4.15 | |
| PFCF ratio | -703.28 | -144.18 | -13.73 | -3.5 | -3.77 | |
| P/B Ratio | -12.79 | 2.3 | 3.61 | 1.98 | 1.69 | |
| PTB ratio | -12.79 | 2.3 | 3.61 | 1.98 | 1.69 | |
| EV to sales | 22.61 | 30.79 | 39.29 | 14.23 | 4.08 | |
| Enterprise value over EBITDA | -35.39 | -8.44 | -9.91 | -2.99 | -2.22 | |
| EV to operating cash flow | 1.17K | -6.86K | -13.85 | -3.44 | -3.86 | |
| EV to free cash flow | -670.12 | -118.42 | -12.98 | -3.2 | -3.5 | |
| Earnings yield | -0.03 | -0.06 | -0.09 | -0.28 | -0.43 | |
| Free cash flow yield | 0 | -0.01 | -0.07 | -0.29 | -0.27 | |
| Debt to equity | -0.08 | 0.03 | 0.04 | 0.04 | 0.15 | |
| Debt to assets | 0.1 | 0.02 | 0.03 | 0.03 | 0.08 | |
| Net debt to EBITDA | 1.75 | 1.84 | 0.57 | 0.29 | 0.17 | |
| Current ratio | 2.44 | 6.7 | 4.7 | 4.51 | 3.4 | |
| Interest coverage | 0 | 0 | 0 | 12.84 | 0 | |
| Income quality | -0.03 | 0 | 0.72 | 0.89 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.27 | 0.92 | 1.05 | 0.98 | 0.56 | |
| Research and developement to revenue | 1.45 | 3.73 | 3.91 | 4.78 | 2.36 | |
| Intangibles to total assets | 0 | 0 | -0.01 | -0.01 | 0 | |
| Capex to operating cash flow | -2.75 | 56.91 | 0.07 | 0.08 | 0.1 | |
| Capex to revenue | -0.05 | -0.26 | -0.19 | -0.32 | -0.11 | |
| Capex to depreciation | -0.7 | -2.09 | -0.93 | -1.13 | -0.62 | |
| Stock based compensation to revenue | 0.02 | 0.24 | 0.53 | 0.73 | 0.44 | |
| Graham number | 4.32 | 33.91 | 22.15 | 21.91 | 14.83 | |
| ROIC | 0.42 | -0.15 | -0.32 | -0.52 | -0.61 | |
| Return on tangible assets | -0.49 | -0.11 | -0.24 | -0.4 | -0.39 | |
| Graham Net | -1.65 | 11.71 | 3.87 | 4.04 | 2.29 | |
| Working capital | 23.22M | 253.9M | 244.86M | 247.79M | 208.55M | |
| Tangible asset value | -57.71M | 290.27M | 345.63M | 307M | 200.49M | |
| Net current asset value | -62.41M | 192.36M | 176.65M | 205.39M | 131.46M | |
| Invested capital | -0.08 | 0.03 | 0.04 | 0.04 | 0.15 | |
| Average receivables | 0 | 5.67M | 8.78M | 3.65M | 950K | |
| Average payables | 1.45M | 2.51M | 5.03M | 5.86M | 5.73M | |
| Average inventory | 0 | 0 | 0.5 | -550K | -550K | |
| Days sales outstanding | 0 | 232.4 | 76.12 | 10.39 | 3.79 | |
| Days payables outstanding | 12.95 | 18.73 | 399.09 | 171.02 | 171.11 | |
| Days of inventory on hand | 0 | 0 | 0 | -37.15 | 0 | |
| Receivables turnover | 0 | 1.57 | 4.8 | 35.12 | 96.23 | |
| Payables turnover | 28.18 | 19.49 | 0.91 | 2.13 | 2.13 | |
| Inventory turnover | 0 | 0 | 6.08M | -9.83 | 0 | |
| ROE | 0.38 | -0.15 | -0.34 | -0.55 | -0.72 | |
| Capex per share | -0.04 | -0.29 | -0.13 | -0.25 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2024-02-29 for Q1
| Metric | History | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 | 2024-02-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.23 | 0.57 | 0.34 | 0.28 | 0.3 | |
| Net income per share | -0.65 | -0.4 | -0.68 | -0.77 | -0.76 | |
| Operating cash flow per share | -0.9 | -0.34 | -0.76 | 0.4 | -0.76 | |
| Free cash flow per share | -0.94 | -0.36 | -0.8 | 0.35 | -0.82 | |
| Cash per share | 5.13 | 5.18 | 4.76 | 5.27 | 4.44 | |
| Book value per share | 5.07 | 4.79 | 4.3 | 3.67 | 3.07 | |
| Tangible book value per share | 5.07 | 4.79 | 4.3 | 3.67 | 3.07 | |
| Share holders equity per share | 5.07 | 4.79 | 4.3 | 3.67 | 3.07 | |
| Interest debt per share | 0.1 | 0.13 | 0.15 | 0.7 | 0.53 | |
| Market cap | 509.49M | 549.1M | 462.32M | 340.05M | 678.06M | |
| Enterprise value | 486.58M | 499.48M | 428.02M | 316.04M | 657.4M | |
| P/E ratio | -3.6 | -6.3 | -3.13 | -2.03 | -4.08 | |
| Price to sales ratio | 40.16 | 17.9 | 25.04 | 22.43 | 40.88 | |
| POCF ratio | -10.52 | -29.73 | -11.24 | 15.64 | -16.16 | |
| PFCF ratio | -10.04 | -28.09 | -10.61 | 17.74 | -15.12 | |
| P/B Ratio | 1.86 | 2.11 | 1.98 | 1.7 | 4.02 | |
| PTB ratio | 1.86 | 2.11 | 1.98 | 1.7 | 4.02 | |
| EV to sales | 38.36 | 16.28 | 23.18 | 20.85 | 39.64 | |
| Enterprise value over EBITDA | -11.33 | -21.32 | -11.69 | -7.6 | -15.91 | |
| EV to operating cash flow | -10.04 | -27.04 | -10.41 | 14.53 | -15.67 | |
| EV to free cash flow | -9.59 | -25.55 | -9.82 | 16.49 | -14.66 | |
| Earnings yield | -0.07 | -0.04 | -0.08 | -0.12 | -0.06 | |
| Free cash flow yield | -0.1 | -0.04 | -0.09 | 0.06 | -0.07 | |
| Debt to equity | 0.04 | 0.04 | 0.03 | 0.15 | 0.17 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.08 | 0.09 | |
| Net debt to EBITDA | 0.53 | 2.12 | 0.94 | 0.58 | 0.5 | |
| Current ratio | 4.44 | 4.01 | 4.36 | 3.4 | 2.86 | |
| Interest coverage | 7.96 | 10.76 | 0 | -5.75 | 0 | |
| Income quality | 1.19 | 0.76 | 1.11 | -0.52 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.77 | 0.38 | 0.58 | 0.71 | 0.71 | |
| Research and developement to revenue | 3.61 | 1.49 | 2.59 | 3.15 | 2.89 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.05 | 0.06 | 0.06 | -0.12 | 0.07 | |
| Capex to revenue | -0.18 | -0.04 | -0.13 | -0.17 | -0.17 | |
| Capex to depreciation | -0.72 | -0.32 | -0.73 | -0.69 | -0.74 | |
| Stock based compensation to revenue | 0.67 | 0.28 | 0.46 | 0.53 | 0.47 | |
| Graham number | 8.64 | 6.58 | 8.11 | 7.96 | 7.23 | |
| ROIC | -0.13 | -0.09 | -0.16 | -0.21 | -0.21 | |
| Return on tangible assets | -0.1 | -0.06 | -0.12 | -0.12 | -0.13 | |
| Graham Net | 3.36 | 3.52 | 3.42 | 2.28 | 1.83 | |
| Working capital | 223.45M | 217.75M | 206.46M | 208.55M | 163.35M | |
| Tangible asset value | 274.05M | 259.92M | 233.82M | 200.49M | 168.75M | |
| Net current asset value | 192.23M | 199.31M | 193.57M | 131.46M | 107.04M | |
| Invested capital | 0.04 | 0.04 | 0.03 | 0.15 | 0.17 | |
| Average receivables | 1.15M | 1.1M | 1.5M | 1.4M | 800K | |
| Average payables | 5.35M | 5.08M | 3.36M | 4.29M | 6.16M | |
| Average inventory | -1.15M | -1.1M | -500K | 0.5 | 0 | |
| Days sales outstanding | 8.51 | 2.93 | 9.75 | 4.75 | 4.34 | |
| Days payables outstanding | 159.31 | 122.19 | 58.16 | 153.34 | 136.99 | |
| Days of inventory on hand | -33.96 | -27 | 0 | 0 | 0 | |
| Receivables turnover | 10.57 | 30.68 | 9.23 | 18.95 | 20.73 | |
| Payables turnover | 0.56 | 0.74 | 1.55 | 0.59 | 0.66 | |
| Inventory turnover | -2.65 | -3.33 | 3.38M | 0 | 0 | |
| ROE | -0.13 | -0.08 | -0.16 | -0.21 | -0.25 | |
| Capex per share | -0.04 | -0.02 | -0.05 | -0.05 | -0.05 |
NRIX Frequently Asked Questions
What is Nurix Therapeutics, Inc. stock symbol ?
Nurix Therapeutics, Inc. is a US stock , located in San francisco of Ca and trading under the symbol NRIX
What is Nurix Therapeutics, Inc. stock quote today ?
Nurix Therapeutics, Inc. stock price is $14.41 today.
Is Nurix Therapeutics, Inc. stock public?
Yes, Nurix Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 855.74K
- Market Capitalization 818.49M
- Employee 284
- CEO Dr. Arthur T. Sands M.D., Ph.D.
- Headquarters San Francisco,CA,US
- IPO Date 2020-07-24
-
Website
https://www.nurixtx.com 
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
